Effects of Stellate Ganglion Block on Delirium and Circadian Rhythm in Geriatric Intensive Care Patients
Key facts
- Who runs it
- Antalya Training and Research Hospital
- Where
- Türkiye1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- People taking part
- 130 people, planned
- Started
- 6 Aug 2026
- Expected to end
- 1 Feb 2027
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- stellate ganglion block with 0.5% bupivacaine
- Placebo Injection
- Record updated
- 22 September 2026
Who can take part
- Age
- 65 years to 99 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (16)Hide the full registry criteria
Who can take part
- Patients aged 65 years or older expected to remain in the intensive care unit for more than 48 hours
- RASS score > -4
Who cannot take part
- History of neurodegenerative disease (e.g., Alzheimer's disease, dementia, vascular dementia)
- Uncontrolled psychiatric disorders
- Alcohol use disorder and/or substance abuse
- History of traumatic brain injury or ischemic/hemorrhagic cerebrovascular event
- Severe hearing and/or visual impairment
- Renal failure (Acute Kidney Injury stage 2-3) and/or liver failure
- Contraindications to stellate ganglion block (e.g., coagulopathy, glaucoma, recent myocardial infarction)
- Allergy to bupivacaine
- Benzodiazepine use
- Beta-blocker use
- Sepsis
- Inability to communicate in Turkish or English
- Severe hyponatremia
- Hemodynamic instability
Eligibility questionnaire
From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Age
- Stellate ganglion block
This trial is currently available in Türkiye.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Delirium is a common complication in elderly intensive care unit (ICU) patients and is associated with poor clinical outcomes. Circadian rhythm disruption is considered an important contributing factor in delirium development. Stellate ganglion block (SGB) may modulate autonomic nervous system activity and improve circadian rhythm regulation.
Read full original descriptionShow less
This prospective randomized placebo-controlled trial aims to evaluate the effects of ultrasound-guided stellate ganglion block on delirium incidence and circadian rhythm in ICU patients aged 65 years and older. Delirium will be assessed using validated clinical scales, and circadian rhythm will be evaluated through serial measurements of serum melatonin and plasma cortisol levels
The 2 groups in the trial
- Placebo GroupPlacebo, for comparison
Ultrasound-guided intramuscular injection of 2 mL normal saline to the anterolateral cervical region
Treatment: Placebo Injection
- Stellate Ganglion Block GroupTreatment being tested
Ultrasound-guided stellate ganglion block using 5 mL of 0.5% bupivacaine
Treatment: stellate ganglion block with 0.5% bupivacaine
Next steps
For your doctor
Doctor ask sheet
A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.
PDF, US Letter, 1 to 2 pages. A4 size
For the study team
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Effects of Stellate Ganglion Block on Delirium and Circadian Rhythm in Geriatric Intensive Care Patients: A Prospective Randomized Controlled Trial
- Criteria questions
- Built from NCT07558642, who can take part
- Record updated
- 22 September 2026